QuickView for Thioridazine (compound)

Summary
General Info

PubChem

PubChem Compound 5452

Name:	Thioridazine
PubChem Compound ID:	5452
Description:	A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.
Molecular formula:	C₂₁H₂₆N₂S₂
Molecular weight:	370.577 g/mol
Synonyms:	Mellaril-S (TN); Sonapax hydrochloride; Malloryl; Mellerets; 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine; Phenothiazine, 10-[2-(1-methyl-2-piperidyl)ethyl]-2-(methylthio)-; Phenothiazine, 10-((1-methyl-2-piperidyl)ethyl)-2-(methylthio)-; 57129-06-3; Melleretten; Spectrum_001066. show more » Mellaril-S (TN); Sonapax hydrochloride; Malloryl; Mellerets; 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine; Phenothiazine, 10-[2-(1-methyl-2-piperidyl)ethyl]-2-(methylthio)-; Phenothiazine, 10-((1-methyl-2-piperidyl)ethyl)-2-(methylthio)-; 57129-06-3; Melleretten; Spectrum_001066; KBio2_004876; Spectrum4_000356; Spectrum2_001332; (+-)-Thioridazine; KBioGR_000791; KBio2_004114; Thioxidazine; 2-Methylmercapto-10-[2-(N-methyl-2-piperidyl)ethyl]phenothiazine hydrochloride; Mellaril-S; Prestwick1_000078; NINDS_000066; AIDS-040821; Thioridazine hydrochloride; KBio2_002308; KBio1_000066; Thioridazine; Melleril; HSDB 3189; 10-[2-(1-Methyl-2-piperidyl)ethyl]-2-methylthiophenothiazine hydrochloride; Mellaril; AIDS040821; Usaf sz-b; 10H-Phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylthio)-; Mellerette; KBioGR_002308; EINECS 200-044-2; Tioridazina [INN-Spanish]; Thioridazin; Usaf sz-3; DivK1c_000066; Thioridazine [USAN:BAN:INN]; KBio2_001546; Melleril (liquid); dl-Thioridazine; 130-61-0; D00373; Thioridazine prolongatum; Thioridazine (USP); Spectrum3_000585; NSC186060; 50-52-2; KBioSS_001546; Phenothiazine, 10-[2- (1-methyl-2-piperidyl)ethyl]-2-(methylthio)-, monohydrochloride; Sonapax; Mellaril hydrochloride; KBioSS_002310; KBio2_007444; Mallorol; Mellaril (Hydrochloride); Tioridazin; AI3-51923; Metlaril; Prestwick0_000078; 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine; 10H-Phenothiazine, 10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylthio)-; 10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methylthio)phenothiazine; SPBio_002216; Thioridazine chloride; KBio3_002788; TP-21; Thioridazinum [INN-Latin]; SPBio_001483; 10H-Phenothiazine, 10-[2- (1-methyl-2-piperidinyl)ethyl]-2-(methylthio)-, monohydrochloride; KBio3_001530; KBio2_006682; Thoridazine hydrochloride; Meleril show less «

DrugBank

Identification

Name:	Thioridazine
Name (isomeric):	DB00679
Drug Type:	small molecule
Description:	A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.
Synonyms:	Thoridazine Hydrochloride; Thioridazine Chloride; Thioridazine Hcl; Thioridazin; Thioridazine Hydrochloride
Brand:	Ridazin, Mellerets, Malloryl, Mellaril, Sonapax, Sonapax Hydrochloride, Ridazine, Melleretten, Aldazine, Mellaril Hydrochloride, Thioridazine, Prolongatum, Mellerette, Metlaril, Tioridazin, Stalleril, Orsanil, Mallorol, Novoridazine, Mellarit, Mellaril-S, Melleril, Thioridazine Hcl Intensol, Meleril
Category:	Phenothiazines, Dopamine Antagonists, Antipsychotic Agents, Antipsychotics
CAS number:	50-52-2

Pharmacology

Indication:	For the treatment of schizophrenia and generalized anxiety disorder.
Pharmacology:	Thioridazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Thioridazine has not been shown effective in the management of behaviorial complications in patients with mental retardation.
Mechanism of Action:	Thioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.
Absorption:	60%
Protein binding:	95%
Biotransformation:	Hepatic
Half Life:	21-25 hours
Toxicity:	LD₅₀=956-1034 mg/kg (Orally in rats); Agitation, blurred vision, coma, confusion, constipation, difficulty breathing, dilated or constricted pupils, diminished flow of urine, dry mouth, dry skin, excessively high or low body temperature, extremely low blood pressure, fluid in the lungs, heart abnormalities, inability to urinate, intestinal blockage, nasal congestion, restlessness, sedation, seizures, shock
Affected organisms:	Humans and other mammals

Interactions

Drug interaction:

Erythromycin	Increased risk of cardiotoxicity and arrhythmias
Grepafloxacin	Increased risk of cardiotoxicity and arrhythmias
Pentamidine	Increased risk of cardiotoxicity and arrhythmias
Levofloxacin	Increased risk of cardiotoxicity and arrhythmias
Amphetamine	Decreased anorexic effect, may increase psychotic symptoms

Erythromycin	Increased risk of cardiotoxicity and arrhythmias
Grepafloxacin	Increased risk of cardiotoxicity and arrhythmias
Pentamidine	Increased risk of cardiotoxicity and arrhythmias
Levofloxacin	Increased risk of cardiotoxicity and arrhythmias
Amphetamine	Decreased anorexic effect, may increase psychotic symptoms
Metrizamide	Increased risk of convulsions
Triprolidine	The antihistamine, Triprolidine, may increase the arrhythmogenic effect of the phenothiazine, Thioridazine. Monitor for symptoms of ventricular arrhythmias. Additive anticholinergic and CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.
Sparfloxacin	Increased risk of cardiotoxicity and arrhythmias
Tetrabenazine	May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.
Tranylcypromine	Tranylcypromine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Thioridazine. Concomitant therapy is contraindicated.
Bretylium	Increased risk of cardiotoxicity and arrhythmias
Phenylpropanolamine	Decreased anorexic effect, may increase psychotic symptoms
Tramadol	Thioridazine may decrease the effect of Tramadol by decreasing active metabolite production.
Doxepin	Increased risk of cardiotoxicity and arrhythmias
Flecainide	Increased risk of cardiotoxicity and arrhythmias
Maprotiline	Increased risk of cardiotoxicity and arrhythmias
Toremifene	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
Terbinafine	Terbinafine may increase serum concentrations of Thioridazine. Concomitant therapy is contraindicated.
Bromocriptine	The phenothiazine decreases the effect of bromocriptine
Tamsulosin	Thioridazine, a CYP2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Thioridazine is initiated, discontinued, or dose changed.
Lumefantrine	Additive QTc-prolongation may occur. Concomitant therapy should be avoided.
Thiothixene	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
Guanethidine	Thioridazine may decrease the effect of guanethidine.
Haloperidol	Increased risk of cardiotoxicity and arrhythmias
Ranolazine	Possible additive effect on QT prolongation
Dextroamphetamine	Decreased anorexic effect, may increase psychotic symptoms
Sotalol	Increased risk of cardiotoxicity and arrhythmias
Ziprasidone	Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.
Methamphetamine	Decreased anorexic effect, may increase psychotic symptoms
Mazindol	Decreased anorexic effect, may increase psychotic symptoms
Artemether	Additive QTc-prolongation may occur. Concomitant therapy is contraindicated.
Pimozide	Increased risk of cardiotoxicity and arrhythmias
Atomoxetine	The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine
Quinidine barbiturate	Increased risk of cardiotoxicity and arrhythmias
Galantamine	Possible antagonism of action
Astemizole	Increased risk of cardiotoxicity and arrhythmias
Trimethobenzamide	Trimethobenzamide and Thioridazine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Sertindole	Increased risk of cardiotoxicity and arrhythmias
Quinidine	Increased risk of cardiotoxicity and arrhythmias
Gatifloxacin	Increased risk of cardiotoxicity and arrhythmias
Phenmetrazine	Decreased anorexic effect, may increase psychotic symptoms
Rivastigmine	Possible antagonism of action
Fluvoxamine	Increased risk of cardiotoxicity and arrhythmias
Paroxetine	Increased risk of cardiotoxicity and arrhythmias
Diethylpropion	Decreased anorexic effect, may increase psychotic symptoms
Tacrolimus	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
Dexfenfluramine	Decreased anorexic effect, may increase psychotic symptoms
Bupropion	Bupropion may increase the effect and toxicity of thioridazine.
Disopyramide	Increased risk of cardiotoxicity and arrhythmias
Chlorpromazine	Increased risk of cardiotoxicity and arrhythmias
Pindolol	Increased risk of cardiotoxicity and arrhythmias
Penicillin G	Increased risk of cardiotoxicity and arrhythmias
Phentermine	Decreased anorexic effect, may increase psychotic symptoms
Imipramine	Increased risk of cardiotoxicity and arrhythmias
Voriconazole	Additive QTc prolongation may occur. Concomitant use is contraindicated.
Donepezil	Possible antagonism of action
Dofetilide	Increased risk of cardiotoxicity and arrhythmias
Duloxetine	Increased risk of cardiotoxicity and arrhythmias
Trimipramine	May cause additive QTc-prolonging effects. Concomitant therapy is contraindicated.
Josamycin	Increased risk of cardiotoxicity and arrhythmias
Propafenone	Increased risk of cardiotoxicity and arrhythmias.
Spiramycin	Increased risk of cardiotoxicity and arrhythmias
Telithromycin	Telithromycin may increase the QTc-prolonging effect of Thioridazine. Concomitant therapy should be avoided.
Tamoxifen	Thioridazine may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy.
Benzphetamine	Antipsychotics may diminish the stimulatory effect of Amphetamines. Monitor effectiveness of amphetamine therapy when altering concurrent antipsychotic therapy as antipsychotic agents may impair the stimulatory effect of amphetamines.
Tacrine	The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Thioridazine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.
Vorinostat	Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).
Chloroquine	Increased risk of cardiotoxicity and arrhythmias
Terfenadine	Increased risk of cardiotoxicity and arrhythmias
Propranolol	Increased risk of cardiotoxicity and arrhythmias
Procainamide	Increased risk of cardiotoxicity and arrhythmias
Halofantrine	Increased risk of cardiotoxicity and arrhythmias
Phendimetrazine	Decreased anorexic effect, may increase psychotic symptoms
Fluoxetine	Increased risk of cardiotoxicity and arrhythmias
Diphenhydramine	Increased risk of cardiotoxicity and arrhythmias
Quinine	Increased risk of cardiotoxicity and arrhythmias
Fenfluramine	Decreased anorexic effect, may increase psychotic symptoms
Amiodarone	Increased risk of cardiotoxicity and arrhythmias
Trospium	Trospium and Thioridazine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.
Amitriptyline	Increased risk of cardiotoxicity and arrhythmias
Zuclopenthixol	Additive QTc-prolonging effects increases risk of cardiac arrhythmias. Concomitant therapy is contraindicated.
Ticlopidine	Ticlopidine may decrease the metabolism of Thioridazine. Concomitant therapy is contraindicated.
Diltiazem	Increased risk of cardiotoxicity and arrhythmias
Vilazodone	Thioridazine prescribing information contraindicates the concomitant use of agents that inhibit CYP2D6 isoenzymes. Avoid combination.
Cisapride	Increased risk of cardiotoxicity and arrhythmias

show less «

Targets

D(2) dopamine receptor

D(1A) dopamine receptor

Alpha-1A adrenergic receptor

Alpha-1B adrenergic receptor

5-hydroxytryptamine 2A receptor

Potassium voltage-gated channel subfamily H member 2

Enzymes